View in EDS

2936eP Immune checkpoint inhibitor rechallenge in combination with siltuximab prophylaxis for patients who had prior immune-related adverse event: Preliminary safety results from the phase 2 CIRES trial.

Saved in:
Bibliographic Details
Title: 2936eP Immune checkpoint inhibitor rechallenge in combination with siltuximab prophylaxis for patients who had prior immune-related adverse event: Preliminary safety results from the phase 2 CIRES trial.
Authors: Yang, Y.A.1 (AUTHOR), Mortazavi, A.1 (AUTHOR), Presley, C.1 (AUTHOR), Konda, B.1 (AUTHOR), Backes, F.2 (AUTHOR), Mittra, A.1 (AUTHOR), Hasanov, M.1 (AUTHOR), Zimmerman, D.1 (AUTHOR), Leibner, D.1 (AUTHOR), Wu, R.1 (AUTHOR), rubinstein, M.1 (AUTHOR), Wei, L.3 (AUTHOR), Meara, A.1 (AUTHOR), Owen, D.H.1 (AUTHOR), Li, Z.1 (AUTHOR), Verschraegen, C.1 (AUTHOR), Li, M.1 (AUTHOR)
Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1538-S1538. 1p.
Database: Academic Search Ultimate
FullText Text:
  Availability: 0
Header DbId: asn
DbLabel: Academic Search Ultimate
An: 189421307
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: 2936eP Immune checkpoint inhibitor rechallenge in combination with siltuximab prophylaxis for patients who had prior immune-related adverse event: Preliminary safety results from the phase 2 CIRES trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AR" term="%22Yang%2C+Y%2EA%2E%22">Yang, Y.A.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mortazavi%2C+A%2E%22">Mortazavi, A.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Presley%2C+C%2E%22">Presley, C.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Konda%2C+B%2E%22">Konda, B.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Backes%2C+F%2E%22">Backes, F.</searchLink><relatesTo>2</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Mittra%2C+A%2E%22">Mittra, A.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Hasanov%2C+M%2E%22">Hasanov, M.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Zimmerman%2C+D%2E%22">Zimmerman, D.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Leibner%2C+D%2E%22">Leibner, D.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wu%2C+R%2E%22">Wu, R.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22rubinstein%2C+M%2E%22">rubinstein, M.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Wei%2C+L%2E%22">Wei, L.</searchLink><relatesTo>3</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Meara%2C+A%2E%22">Meara, A.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Owen%2C+D%2EH%2E%22">Owen, D.H.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Li%2C+Z%2E%22">Li, Z.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Verschraegen%2C+C%2E%22">Verschraegen, C.</searchLink><relatesTo>1</relatesTo> (AUTHOR)<br /><searchLink fieldCode="AR" term="%22Li%2C+M%2E%22">Li, M.</searchLink><relatesTo>1</relatesTo> (AUTHOR)
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22Annals+of+Oncology%22">Annals of Oncology</searchLink>. 2025 Supplement 2, Vol. 36, pS1538-S1538. 1p.
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=asn&AN=189421307
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/j.annonc.2025.08.3548
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        PageCount: 1
        StartPage: S1538
    Titles:
      – TitleFull: 2936eP Immune checkpoint inhibitor rechallenge in combination with siltuximab prophylaxis for patients who had prior immune-related adverse event: Preliminary safety results from the phase 2 CIRES trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Yang, Y.A.
      – PersonEntity:
          Name:
            NameFull: Mortazavi, A.
      – PersonEntity:
          Name:
            NameFull: Presley, C.
      – PersonEntity:
          Name:
            NameFull: Konda, B.
      – PersonEntity:
          Name:
            NameFull: Backes, F.
      – PersonEntity:
          Name:
            NameFull: Mittra, A.
      – PersonEntity:
          Name:
            NameFull: Hasanov, M.
      – PersonEntity:
          Name:
            NameFull: Zimmerman, D.
      – PersonEntity:
          Name:
            NameFull: Leibner, D.
      – PersonEntity:
          Name:
            NameFull: Wu, R.
      – PersonEntity:
          Name:
            NameFull: rubinstein, M.
      – PersonEntity:
          Name:
            NameFull: Wei, L.
      – PersonEntity:
          Name:
            NameFull: Meara, A.
      – PersonEntity:
          Name:
            NameFull: Owen, D.H.
      – PersonEntity:
          Name:
            NameFull: Li, Z.
      – PersonEntity:
          Name:
            NameFull: Verschraegen, C.
      – PersonEntity:
          Name:
            NameFull: Li, M.
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 02
              M: 09
              Text: 2025 Supplement 2
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-print
              Value: 09237534
          Numbering:
            – Type: volume
              Value: 36
          Titles:
            – TitleFull: Annals of Oncology
              Type: main
ResultId 1